VANCOUVER, Aug. 7, 2018 /CNW/ - INVICTUS MD
STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX:
IVITF; FRA: 8IS1) is pleased to announce that its wholly owned
subsidiary, Acreage Pharms Ltd. ("Acreage Pharms"), has
received an amended license from Health Canada, under the Access to
Cannabis for Medical Purposes Regulations ("ACMPR"), to
include the production of bottled cannabis oil and cannabis resin,
effective August 3, 2018.
Acreage Pharms' state-of-the-art closed-loop CO2
extraction process produces the highest-quality cannabis oils in
the world. The system performs Subcritical and Supercritical Fluid
Extraction utilizing high-pressure carbon dioxide to extract
essential oils from botanicals, using specific temperatures and
pressures to withdraw different components from plants. Through
this extraction process, CBD and THC levels can be adjusted to
ensure a diverse selection for consumers.
"We are building a robust portfolio of flower and oil products
to satisfy consumer demand in both the medical and recreational
markets," said Dan Kriznic, Chairman
and CEO of Invictus. "Research shows CBD products are increasing in
popularity, but the market is still unknown. We need to be able to
adjust our product offerings as the market evolves over time."
Compared to solvent extractions, Acreage Pharms Supercritical
CO2 extraction will be:
- Non-Toxic and Non-Carcinogenic. Oils extracted using
CO2 do not contain petroleum particles.
- Safe. The system does not use potentially flammable or
explosive petroleum-based solvents.
- Carbon-Neutral and Environmentally Friendly. The system does
not emit carbon.
- Customizable. With a wide range of temperatures, pressures and
flow rates to leverage, the system is capable of withdrawing full
profiles of natural compounds found within cannabis.
- Premium quality. The advanced system is used by top companies
to extract coffee, vanilla, tea, fruit and nuts, omega-3 oils,
fragrances, tobacco for e-cigarettes, hop-oil for beer, and
high-grade cannabis oil.
Acreage Pharms' oil extraction and quality assurance program
will be overseen by registered Pharmacist and Responsible Person in
Charge, Chris Kooner, supported by a
skilled technical team of PHD's and experienced cultivators.
For more information, please visit www.invictus-md.com.
On Behalf of the Board,
Dan Kriznic
Chairman and CEO
Jessica Martin
Vice President, Public Relations and Regulatory Affairs
(647) 828-9655
About Invictus
Invictus is a global cannabis company offering a selection of
products under a wide range of lifestyle brands. Our integrated
sales approach is defined by five pillars of distribution including
medical, wholesale, international, Licensed Producer to Licensed
Producer and retail.
Invictus has partnered with business leaders to convey our
corporate vision, including KISS music legend and business mogul
Gene Simmons as our Chief Evangelist
Officer, and global branding agency Authentic Brands Group.
Invictus is expanding its cultivation footprint, with two cannabis
production facilities fully licensed under ACMPR in Canada and a third awaiting approval,
featuring 100,000 square feet of available grow space today with
200,000 expected by the end of 2018 and 1 million by end of 2019.
The Company will earmark 50 per cent of production to the medical
and recreational markets, respectively. To ensure consistency in
quality and supply, Invictus maintains all aspects of the growing
process through its subsidiary, Future Harvest Development Ltd., a
high-quality Fertilizer and Nutrients manufacturer. Invictus drives
sustainable long-term shareholder value through a diversified
product portfolio with over 69 Health Canada approved strains and a
multifaceted distribution strategy including medial, recreational,
international and retail. For more information visit
www.invictus-md.com.
Cautionary Note Regarding Forward-Looking Statements: This
release includes certain statements and information that may
constitute forward-looking information within the meaning of
applicable Canadian securities laws or forward-looking statements
within the meaning of the United States Private Securities
Litigation Reform Act of 1995. All statements in this news release,
other than statements of historical facts, including statements
regarding future estimates, plans, objectives, timing, assumptions
or expectations of future performance, including the potential
acquisition of OptionCo pursuant to the exercise of the Option, and
the potential production capacity of OptionCo, AB Labs, AB Ventures
and Acreage Pharms, are forward-looking statements and contain
forward-looking information. Generally, forward-looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should", "would" or "occur".
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release,
including that the Company will be successful in exercising the
Option and obtaining TSX Venture Exchange approval of the
acquisition, that OptionCo and AB Labs will be successful in
reaching their potential production capacity, OptionCo, AB Ventures
and Acreage Pharms' production facilities will be completed as
anticipated, regulatory approval will be granted as anticipated,
OptionCo and AB Labs will reach full production capacity on the
timeline anticipated by the Company, OptionCo will be granted its
first and second licenses, AB Labs will be granted its secondary
license on the terms and timeline anticipated by the Company, no
unforeseen construction delays will be experienced, and OptionCo
and Acreage Pharms will be granted its sales license under the
ACMPR on the terms and timeline anticipated by the Company,.
These forward-looking statements are subject to known and unknown
risks, uncertainties and other factors that may cause the actual
results, level of activity, performance or achievements of the
Company to be materially different from those expressed or implied
by such forward-looking statements or forward-looking information.
Important factors that may cause actual results to vary, include,
without limitation, the Company will not complete the
acquisition of OptionCo, OptionCo and AB Labs will not be
successful in reaching its potential production capacity, OptionCo,
AB Ventures and Acreage Pharms' production facilities will not be
completed as anticipated, construction delays, regulatory approval
will not be granted as anticipated and therefore, the anticipated
timing of OptionCo and AB Labs reaching full production capacity
will be delayed, AB Labs will not be granted their secondary
license, OptionCo will not be granted its first and second
licenses and OptionCo and Acreage Pharms will not be granted its
sales license under the ACMPR, and licenses or approvals being
granted on terms or timelines that are materially worse than
expected by the Company. Although management of the Company
has attempted to identify important factors that could cause actual
results to differ materially from those contained in
forward-looking statements or forward-looking information, there
may be other factors that cause results not to be as anticipated,
estimated or intended. There can be no assurance that such
statements will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on
forward-looking statements and forward-looking information. Readers
are cautioned that reliance on such information may not be
appropriate for other purposes. The Company does not undertake to
update any forward-looking statement, forward-looking information
or financial out-look that are incorporated by reference herein,
except in accordance with applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original content with
multimedia:http://www.prnewswire.com/news-releases/invictus-acreage-pharms-receives-oil-extraction-license-from-health-canada-300693165.html
SOURCE Invictus MD Strategies